5-mRNA-based prognostic signature of survival in lung adenocarcinoma

Figure 1 Screening of differential genes and establishing LASSO regression. A: Volcano map of the differential genes in the GSE43458; B: Volcano map of the differential genes in the GSE32863; C: Volcano map of the differential genes in the GSE27262; D: Venn diagram of the three Gene Expression Omnibus datasets; E: LASSO coefficients profiles of 380 common differential genes; F: LASSO regression with ten- fold cross-validation constructed the models.

Figure 2 The expression and genetic alterations of the 5 prognostic genes in Lung adenocarcinoma. A: Genetic alterations rate of 5 model genes; B: Differential expression of the mRNA levels in lung adenocarcinoma tissues; C: Differential expression at the protein levels of the five model genes.

Figure 3 Risk score model, time-dependent receiver operating characteristic analysis, and survival analysis for the 5-gene signature in Lung adenocarcinoma. A: The risk score curve divided the patients into the high-risk and low-risk groups; B: Distribution map of the patient's survival status; C: Heatmap of model genes in high and low risk groups; D: Kaplan-Meier survival analysis of the 5-mRNA-based prognostic signature; E: Receiver operating characteristic curves to evaluate the prognostic signature; F: Multiple cox regression analysis of the risk scores and clinical parameters.

Figure 4 Internal and external validation of the 5-gene prognostic signature. A: Internal validation by survival analysis; B: The entire dataset validation by survival analysis; C: GSE11969-based external validation by survival analysis; D: Internal validation by receiver operating characteristic (ROC) curves; E: The entire dataset validation by ROC curves; F: GSE11969-based external validation by ROC curves.